15
Oct
2024
Designing Protein Drugs for Cancer & Autoimmunity: Chris Garcia on The Long Run
Today’s guest on The Long Run is K. Christopher Garcia. Chris is a professor of molecular and cellular physiology and structural biology at Stanford University and an investigator for the Howard Hughes Medical Institute. To be a bit more specific, you can call him a structural immunologist – the kind of scientist who uses the vivid tools of structural biology... Read More
10
Oct
2024
Nobel for Protein Design and AlphaFold, Scholar Rock Shines, and a City is Born
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
10
Oct
2024
Booster Gets $15M from Apollo, Novo to Develop Proteasome Activators for Neurodegeneration
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
9
Oct
2024
Basecamp Research Secures $60M to Hone First Principles for AI Drug Discovery
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
8
Oct
2024
Call for Entries: Join the Timmerman Traverse for Damon Runyon Cancer Research
Are you ready for a bucket list adventure? Join me and a team of biotech executives and investors on the Timmerman Traverse for Damon Runyon Cancer Research Foundation. It’s a trek to Everest Base Camp (17,600 feet) in April 2025. Who’s on the Team? Luke Timmerman, founder & editor, Timmerman Report (team captain) Soufiane Aboulhouda, co-founder and CEO, Nucleate Tamar... Read More
3
Oct
2024
BioAge Goes Public, Kailera Piles into GLP-1, and Lilly Bets Big on Indiana
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
2
Oct
2024
Triveni Bio Secures $115M to Treat Immune & Inflammatory Diseases
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
26
Sep
2024
Pfizer Withdraws Sickle Cell Drug, Arch Hauls in $3B, and BMS Wins Schizophrenia OK
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
26
Sep
2024
Boundless Bio Takes on Oncogene Amplified Cancers: Zach Hornby on The Long Run
Zach Hornby is today’s guest on The Long Run. Zach is the CEO of San Diego-based Boundless Bio. The company is seeking to target cancer cells in an unusual way. It is developing small molecule drugs that take aim at DNA that resides outside the usual home on a chromosome. These oncogene amplifications occur in loops outside the chromosome. This... Read More
17
Sep
2024
Sickle Cell Patient Cured With CRISPR Summits Kilimanjaro, Setting World Record
Four years after being functionally cured of sickle cell disease with a CRISPR gene-editing therapy, Jimi Olaghere has set a new world record for patients with this chronic and deadly disease. Olaghere, a 39-year-old business owner from Atlanta, became the world’s first patient with sickle cell disease to reach the summit of Kilimanjaro at 7:30 am Tanzania time on Sept.... Read More
10
Sep
2024
Amy Abernethy, Brad Hirsch Aim for Better Medical Evidence With Highlander Health
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
9
Sep
2024
Candid Therapeutics Emerges with $370M to Develop T-Cell Engagers for Autoimmunity
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
9
Sep
2024
The Enchantments Traverse: A Photo Gallery
The 4th annual Timmerman Traverse for Life Science Cares wrapped up last month, but I’m feeling a bit remiss for not telling the whole story. This year’s successful $1 million campaign came in two parts. First, there were a pair of back-to-back day hikes in the North Cascades with a team composed mostly of newcomers to the Life Science Cares... Read More
5
Sep
2024
Raising the Bar for Sickle Cell Patients: Ted Love and Alan Anderson on The Long Run
Today’s guests on The Long Run are Ted Love and Alan Anderson. Ted is the chairman of the board of directors at the Biotechnology Innovation Organization. He’s perhaps best known for serving as CEO of Global Blood Therapeutics, the San Francisco Bay Area company that developed voxelotor (marketed as Oxbryta), a novel small molecule for sickle cell disease. The company... Read More
4
Sep
2024
Arsenal Bio Fetches $325M To Make CAR-T Therapies for Solid Tumors
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
26
Aug
2024
Timmerman Traverse for Life Science Cares Hits $1M Goal to Fight Poverty
We did it! The Timmerman Traverse for Life Science Cares wrapped up last week. This team of biotech executives and investors hit its goal of raising $1 million to fight poverty in the United States. We hiked about 20 miles together, gaining between 6,000 and 8,000 vertical feet of elevation in the North Cascades of Washington state. This trip had... Read More
14
Aug
2024
RNA Medicines to Treat Muscle Diseases: Sarah Boyce on The Long Run
Today’s guest on The Long Run is Sarah Boyce. She is the CEO of San Diego-based Avidity Biosciences. Avidity is a developer of RNA medicines. It uses what it calls “antibody oligonucleotide conjugates”. These are molecules that connect an antibody — which hits a specific target on the surface of cells – with an RNA-silencing molecule. That RNA molecule can... Read More
8
Aug
2024
Recursion Scoops up Rival, Servier’s Brain Cancer Win, & Cell Therapy for Solid Tumors
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
25
Jul
2024
PBMs Feel the Heat, Megarounds Abound, and the XBI Tops 100
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
16
Jul
2024
Biologic Drug Discovery With AI: Sean McClain on The Long Run
Sean McClain is today’s guest on The Long Run. He’s the founder and CEO of Vancouver, Washington-based Absci. Sean started the company on his own in his early 20s, straight out of the University of Arizona, with the encouragement of his Dad. You could call it a scrappy garage biotech, with no traditional VC backers at first. He found a... Read More